Bio-Techne Corp
TECH Mid CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Bio-Techne Corp en bref
Bio-Techne Corp (TECH) is currently trading at 50,56 € with a market capitalization of 7,9 Md €. The trailing P/E ratio stands at 82.77x, with a forward P/E of 28.19x. The 52-week range spans from 37,70 € to 62,97 €; the current price is 19.7% below the yearly high. Year-over-year revenue growth stands at -1.5%. The net profit margin stands at 9.05%.
💰 Dividende
Bio-Techne Corp pays an annual dividend of 0,28 € per share, representing a yield of 0.55%. The payout ratio stands at 45.71%.
📊 Avis des analystes
13 analystes évaluent Bio-Techne Corp (TECH) au consensus : Acheter. L'objectif de cours moyen est de 53,84 €, soit un potentiel de +6.48% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 42,76 € à 65,45 €.
Bio-Techne Corp : la thèse d'investissement en détail
Bio-Techne Corp (TECH) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Earnings growth of 128.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 66.4%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue is contracting at -1.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 10.09% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
With a PEG ratio of 0.77, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The forward P/E of 28.19x is meaningfully below the trailing 82.77x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 66.4% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 13.92)
- Free cash flow positif
- –CA en contraction (-1.5% sur un an)
- –Multiple de valorisation élevé (P/E 82.77x)
- –Actuellement jugée surévaluée
- –Positions vendeuses élevées (10.09%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (10.09%).
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Bio-Techne Corp?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news